1. Cancer Cell. 2019 Apr 15;35(4):573-587.e6. doi: 10.1016/j.ccell.2019.03.002. 
Epub 2019 Apr 8.

Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined 
Inhibition of EGFR and C-RAF.

Blasco MT(1), Navas C(1), Martín-Serrano G(2), Graña-Castro O(2), Lechuga CG(1), 
Martín-Díaz L(3), Djurec M(3), Li J(1), Morales-Cacho L(1), Esteban-Burgos L(1), 
Perales-Patón J(2), Bousquet-Mur E(3), Castellano E(3), Jacob HKC(3), Cabras 
L(3), Musteanu M(1), Drosten M(1), Ortega S(4), Mulero F(5), Sainz B Jr(6), 
Dusetti N(7), Iovanna J(7), Sánchez-Bueno F(8), Hidalgo M(9), Khiabanian H(10), 
Rabadán R(10), Al-Shahrour F(2), Guerra C(11), Barbacid M(12).

Author information:
(1)Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas 
(CNIO), 28029 Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria 
(IRYCIS), 28034 Madrid, Spain.
(2)Bioinformatics Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), 
28029 Madrid, Spain.
(3)Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas 
(CNIO), 28029 Madrid, Spain.
(4)Transgenic Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 
Madrid, Spain.
(5)Molecular Imaging Unit, Centro Nacional de Investigaciones Oncológicas 
(CNIO), 28029 Madrid, Spain.
(6)Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, 
Spain; Department of Biochemistry, School of Medicine, Autonomous University of 
Madrid, 28018 Madrid, Spain.
(7)Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS 
UMR 7258, Aix-Marseille Université et Institut Paoli-Calmettes, Parc 
Scientifique et Technologique de Luminy, 163, Avenue de Luminy, 13288 Marseille, 
France.
(8)Department of Surgery, Clinical University Hospital 'Virgen Arrixaca' - 
Murcian Institute of Biomedical Investigation (IMIB), 30120 Murcia, Spain.
(9)Rosenberg Clinical Cancer Center, Beth Israel Deaconess Medical Center, 
Harvard Medical School, Boston, MA, USA.
(10)Department of Systems Biology, Columbia University Medical Center, New York, 
NY 10032, USA.
(11)Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas 
(CNIO), 28029 Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria 
(IRYCIS), 28034 Madrid, Spain. Electronic address: mcguerra@cnio.es.
(12)Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas 
(CNIO), 28029 Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria 
(IRYCIS), 28034 Madrid, Spain. Electronic address: mbarbacid@cnio.es.

Five-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remains 
below 7% due to the lack of effective treatments. Here, we report that combined 
ablation of EGFR and c-RAF expression results in complete regression of a 
significant percentage of PDAC tumors driven by Kras/Trp53 mutations in 
genetically engineered mice. Moreover, systemic elimination of these targets 
induces toxicities that are well tolerated. Response to this targeted therapy 
correlates with transcriptional profiles that resemble those observed in human 
PDACs. Finally, inhibition of EGFR and c-RAF expression effectively blocked 
tumor progression in nine independent patient-derived xenografts carrying KRAS 
and TP53 mutations. These results open the door to the development of targeted 
therapies for PDAC patients.

Copyright © 2019 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccell.2019.03.002
PMCID: PMC10132447
PMID: 30975481 [Indexed for MEDLINE]

Conflict of interest statement: DECLARATION OF INTERESTS M.B. reports a research 
contract from Pfizer and Eli Lilly and paid consultancy from Amcure. J.I. 
reports paid consultancy from Dynasio S.A. and Oncomedics, both in France. M.H. 
reports research contracts and/or paid consultancy with Roche and Astra-Zeneca. 
None of these relationships are related to the work reported in this manuscript. 
We declare a patent application related to this work: EP18382555 Barbacid, M., 
Guerra C., Blasco, M.T., Navas, C. (2018). COMBINED THERAPY AGAINST CANCER.